Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial

References

• Breedveld FC. Osteoarthritis – the impact of a serious disease. Rheumatology (Oxford) 2004;43(Suppl 1):i4-8
   PubMedGoogle Scholar
• Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994;84:351-8
   PubMed Web of Science ®Google Scholar
• Fransen M, Bridgett L, March L, et al. The epidemiology of osteoarthritis in Asia. Int J Rheum Dis 2011;14:113-21
   PubMed Web of Science ®Google Scholar
• Kim I, Kim HA, Seo YI, et al. The prevalence of knee osteoarthritis in elderly community residents in Korea. J Korean Med Sci 2010;25:293-8
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995;38:1535-40
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6
   PubMed Web of Science ®Google Scholar
• Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. Eur J Clin Pharmacol 2013;69:1369-73
   PubMed Web of Science ®Google Scholar
• Peloso PM, Gammaitoni A, Smugar SS, et al. Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskelet Disord 2011;12:165-12
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
   PubMed Web of Science ®Google Scholar
• Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009;104:356-62
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507
   PubMed Web of Science ®Google Scholar
• Daniels SE, Bandy DP, Christensen SE, et al. Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. Clin J Pain 2011;27:1-8
   PubMed Web of Science ®Google Scholar
• Rawal N, Viscusi E, Peloso PM, et al. Evaluation of etoricoxib in patients undergoing total knee replacement surgery in a double-blind, randomized controlled trial. BMC Musculoskelet Disord 2013;14:300-14
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Frenkl TL, Hartrick CT, et al. Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study. Curr Med Res Opin 2012;28:1323-35
   PubMed Web of Science ®Google Scholar
• Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005;64:29-33
   PubMed Web of Science ®Google Scholar
• Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49-58
   PubMed Web of Science ®Google Scholar
• Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009;48:425-32
   PubMed Web of Science ®Google Scholar
• Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1-15
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2
   PubMed Web of Science ®Google Scholar